Loading
ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.
E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.89, genetic association 0.34, somatic mutation 0.36). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Renal Clear Cell Carcinoma.
In plain words · ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.
ATG7 (Ubiquitin-like modifier-activating enzyme ATG7) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Renal cell carcinoma and Clear cell renal cell carcinoma.
E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy.
No product in this corpus aims at ATG7 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it a tumour suppressor (IntOGen finds it knocked out more often than chance); what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ATG7: RNA low tissue specificity; high antibody staining in 2 normal tissues; highest cancer staining glioma (4 of 10 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Pancreatic ductal adenocarcinoma, Renal cell carcinoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O95352; CIViC gene ATG7; IntOGen ATG7; Human Protein Atlas ATG7 tissue; Open Targets ENSG00000197548 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Yuan et al, Mol. Biol. Cell, 1999, "Glucose-induced autophagy of peroxisomes in Pichia pastoris requires a unique E1-like protein". Source.
Sources: HGNC HGNC:16935 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95352 (protein name, function text, keywords and locations (REST API)); CIViC gene ATG7 (1 evidence items, 0 assertions, 1 variants; diseases: Pancreatic Ductal Adenocarcinoma (GraphQL API, CC0)); Open Targets ENSG00000197548 (association with cancer (MONDO_0004992) 0.64; (GraphQL API, CC0)); IntOGen ATG7 (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
E1-like activating enzyme involved in the 2 ubiquitin-like systems required for cytoplasm to vacuole transport (Cvt) and autophagy. Activates ATG12 for its conjugation with ATG5 as well as the ATG8 family proteins for their conjugation with phosphatidylethanolamine. Both systems are needed for the ATG8 association to Cvt vesicles and autophagosomes membranes. Required for autophagic death induced by caspase-8 inhibition. Facilitates LC3-I lipidation with phosphatidylethanolamine to form LC3-II which is found on autophagosomal membranes. Required for mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the mitochondria to a basal level to fulfill cellular energy requirements and preventing excess ROS production. Location: Cytoplasm; Preautophagosomal structure (UniProt). Locus 3p25.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Adrenal gland, Breast, Caudate, Cerebellum, Cerebral cortex, Colon, Duodenum.
Medium only: breast cancer, cervical cancer, endometrial cancer, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ATG7" OR ABSTRACT:"ATG7" OR TITLE:"autophagy related 7" OR ABSTRACT:"autophagy related 7" OR TITLE:"Ubiquitin-like modifier-activating enzyme ATG7" OR ABSTRACT:"Ubiquitin-like modifier-activating enzyme ATG7" OR TITLE:"GSA7" OR ABSTRACT:"GSA7" OR TITLE:"DKFZp434N0735" OR ABSTRACT:"DKFZp434N0735" OR TITLE:"APG7L" OR ABSTRACT:"APG7L") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ATG7, not a curated reading list.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, CIViC, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.
Shares Clear cell renal cell carcinoma, Renal cell carcinoma, IntOGen, Open Targets Platform.